CEC/CEA
_________________________________________________________________
  cytoxan......... 500 mg/sqm IV day 1.
  etoposide....... 80 mg/sqm IV on days 1 to 3.
  cisplatin....... 33 mg/sqm IV on days 1 to 3.
  FREQUENCY....... Repeat cycle every 3 weeks for 5 cycles.

  cytoxan......... 500 mg/sqm IV day 1.
  etoposide....... 80 mg/sqm IV on days 1 to 3.
  adriamycin...... 50 mg/sqm IV day 1.
  FREQUENCY....... Repeat cycle every three weeks for 3 cycles.


  reference...
    Kwiatkowski DJ.  Propert KJ.  Carey RW.  Choi N.  Green M. A 
    phase II trial of cyclophosphamide, etoposide, and cisplatin 
    with combined chest and brain radiotherapy in limited 
    small-cell lung cancer: a Cancer and Leukemia Group B Study. 
    Journal of Clinical Oncology.  5(12):1874-9, 1987 Dec. 
  abstract...
    Limited-extent small-cell lung carcinoma (SCLC) remains a 
    therapeutic problem with little improvement in complete 
    response (CR) rates and long-term survival in the past 5 
    years. From June 1984 through January 1985, 56 patients with 
    limited-extent SCLC were enrolled in a Cancer and Leukemia 
    Group B (CALGB) phase II study using five cycles of 
    cyclophosphamide (500 mg/m2 intravenously [IV] day 1), 
    etoposide (80 mg/m2 IV days 1 to 3), and cisplatin (33 mg/m2 
    IV days 1 to 3) administered at 3-week intervals (CEP), with 
    radiation therapy (50 Gy to chest and 30 Gy to brain) 
    administered concomitant with cycles 4 and 5, followed by 
    three cycles of cyclophosphamide (500 mg/m2 IV day 1), 
    etoposide (80 mg/m2 IV days 1 to 3), and doxorubicin (50 mg/m2 
    IV day 1). Of 49 patients evaluable for response, the overall 
    response rate was 88%, with 57% CRs. The median overall 
    survival was 14 months; the median duration of CR was 10 
    months, and nine CRs remain disease free at a median follow-up 
    of 23 months. Toxicity was significant: 56% patients 
    experienced WBC less than 1,000 microL, 32% platelets less 
    than 25,000 microL and 10% hemoglobin less than 7 g/dL. There 
    was one treatment-related septic death. These results are as 
    good as the best previous CALGB study of SCLC, despite a 
    reduction in duration of treatment from 18 to 5 months. We are 
    currently using a variant of this multimodality treatment 
    approach as our standard management for patients with 
    limited-extent SCLC.